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COMBINED PHARMACOTHERAPY FOR THE TREATMENT OF TRAUMATIC
BRAIN INJURY REHABILITATION AND RECOVERY OF FUNCTION
FOLLOWING PREFRONTAL CORTEX CONTROLLED CORTICAL IMPACT IN
RATS

ABBY N. KYSER
ABSTRACT

Traumatic brain injury (TBI) is common among military personnel, resulting from bomb
blasts and explosions. The secretion of pro-inflammatory cytokines following TBI has
been linked to cerebral edema and neuronal loss. The use of lovastatin for TBI has been
suggested to be neuroprotective by combating cytokines and inflammation. Fluoxetine
has been suggested to aid in the prevention of edema during secondary injury processes,
as well as having a relationship to neural plasticity. Seventy-six Long-Evans rats were
randomly assigned to CCI (controlled cortical impact) or sham-operated as well as one of
the following drug conditions: no treatment, vehicle, Fluoxetine only, Lovastatin only,
and combined Fluoxetine-Lovastatin. Two behavioral tasks testing motor control and
somatosensory input were used to investigate recovery of function. Brain tissue was
analyzed using cresyl violet stain and GFAP label. Behavioral and cell count data did not
reveal significant improvements between combined Fluoxetine-Lovastatin
pharmacotherapy groups and all other groups. Several methodological limitations that
may account for these negative findings are discussed. Although the combination of
Lovastatin and Fluoxetine did not significantly improve behavioral scores or cell counts
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in the patterns expected, the possibility of utilizing a combined pharmacotherapy to treat
TBI or TBI comorbid with other conditions should be investigated further.
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CHAPTER I
INTRODUCTION
Traumatic brain injuries (TBI) happen to approximately 1.5 million Americans a
year (Rutland-Brown, Langlois, & Thomas, 2006), with the National Center for Injury
Prevention and Control estimating the incidence of TBI to be 2% of the population
(1999). Approximately 150,000 to 300,000 returning US soldiers have experienced some
level of TBI during their tour of duty (Emery, 2007). Among Operation Iraqi Freedom
and Operation Enduring Freedom veterans, 30% have experienced a TBI. Of those TBI
patients, 56% have moderate to severe TBI and 44% have mild TBI (Warden, 2006). A
TBI is described as an impact of the brain against the interior of the skull from
accelerating-decelerating forces (Thurman, Alverson, Dunn, et al., 1999). TBI
commonly occurs in motor vehicle and motorcycle accidents, accidental falls, and being
struck by an object. TBI-associated costs are estimated to be over $10 billion a year in
the United States alone, with the average lifetime cost per individual of nearly $2 million
per person (Boswell, McErlean, & Verdile, 2002). Because of the great number of costs
associated with TBI, such an injury is seriously addressed in the research and medical
communities.
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TBI patients have difficulty making choices, adapting to specific situations, and
maintaining motivation (Powell, Al-Adawi, Morgan, & Greenwood, 1996; Schlund,
2002). Such difficulties can make life particularly difficult, especially when it comes to
readjusting and trying to live the same way one did pre-injury. Many TBI sufferers have
difficulty securing and holding onto jobs (Powell et al., 1996). One issue that makes
readjustment particularly difficult is the appearance of sleep disturbances and insomnia
post-injury (Williams, Lazic, & Ogilvie, 2008). Over time, many of the sleep
disturbances will disappear, but some patients will experience persistent sleep
disturbances and insomnia long after the brain injury has occurred (Williams et al., 2008).
Another common issue after brain injury is memory impairment. Although memory
impairment occurs with mild TBI as well, the impairments are more frequent and more
pronounced in moderate to severe TBI. Memory impairments tend to show improvement
within 6 months to 2 years of brain injury (Lannoo, Colardyns, Jannes, et al., 2001), but
deficient learning and memory may be detected in some patients with severe TBI at 10
years post-injury (Zec, Zellers, Belman, et al., 2001). The memory impairments most
likely occur because TBI leads to widespread axonal injury (Ommaya & Gennarelli,
1974) in which the frontal and temporal lobes were found to be the most vulnerable
cortical areas (Adams, 1975). MRI abnormalities have been found in the medial
temporal and lateral frontal lobes in addition to ventricular enlargement (Crosson, Sartor,
Jenny, et al., 1993). Hippocampal atrophy has also been observed following severe TBI
(Bigler, Johnson, Anderson, et al., 1996). Brain activity measured by PET scan during
memory and executive function tasks showed decreased cortical metabolism in the
prefrontal cortex and cingulate gyrus in patients with TBI (Fontaine, Azouvi, Remy, et
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al., 1999). Patients with TBI also showed reduced activation in the frontal lobe and
increased activation in the posterior brain regions during free recall (Fontaine et al.,
1999). The investigators also observed additional activated areas in TBI patients as
opposed to controls when engaging in a cued recall task. It is important to replicate as
much as possible the spectrum of complexities associated with TBI when working with
animal injury models.
Since the brain structure of a rodent is very similar to that of the human brain
(Gennarelli, 1994), animal models of TBI can be used to observe the effects and test
therapies. The most common area affected by TBI is the frontal cortex, especially if the
injury is of an accelerating/decelerating nature. This type of injury can also result in
damage to the lower portions of the brainstem (Van Reekum, Cohen, & Wong, 2000). A
surgical model of frontal medial cortex (MFC) contusion has been used (Hoffman, Fulop,
& Stein, 1994; Smith, Fulop, Levinsohn, et al., 2000) to simulate injuries sustained in a
motor vehicle accident. The use of rodent models for the modeling of human TBI is
widely accepted as a suitable choice for neurotrauma research (Cernak, 2005). One of
the most frequently used models of TBI is fluid percussion injury (FPI). This model
consists of a fluid pressure pulse applied to the intact dura through a craniotomy by
means of a pendulum hitting a saline-filled Plexiglas cylinder cemented onto the skull
over a craniotomy. Unfortunately, there are issues in reproducibility with the FPI model
and it does not reflect the entire complexity of human TBI. There has also been evidence
of some ipsilateral and contralateral damage in addition to the originally intended brain
area (Cernak, 2005). Controlled cortical impact (CCI) is a rodent model of TBI that
allows for better control over mechanical factors such as velocity of impact and depth of
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the resulting deformation. The injury is delivered to the intact dura by an air-driven
piston causing deformation to the underlying cortex through a craniotomy. The CCI
model produces a more focused injury compared to the FPI model, as well as a
replication of clinical brain injury with cortical compression (Cernak, 2005). CCI is
more appropriate when used to analyze mechanisms underlying neuronal cell death and
resulting neurological deficits (Cernak, 2005). There exist other direct brain deformation
models of TBI, but these do not cause significant long-term deficits that would be of
importance in the research of localized contusions. Marmarou’s weight drop model, a
closed head impact acceleration injury, causes trauma by a column of brass weights
falling from a designated height through a Plexiglas tube onto a steel disc that was
cemented centrally onto the skull (Foda & Marmarou, 1994; Marmarou, Foda, van den
Brink, et al., 1994). The rat is placed on a deep foam bed and the impact is generated by
dropping the brass weights onto the stainless steel disc. This model is popular because of
cost and the ease with which the injury is inflicted (Cernak, 2005). However, the
biomechanics of the impact, including velocity, are not completely controlled. This
model has the possibility of a secondary drop, in which the weight rebounds from the
skull of the animal resting on the foam bed (Cernak, 2005). For the purposes of this
study, CCI is a good model for combining the brain injury and secondary insults seen in
human TBI.
In CCI, lesions are generated using a pneumatic piston device to create the
physiological and neurological changes that occur following TBI in humans (Hoffman,
Stein, & Fulop, 1994; Smith et al., 2000). Using a pneumatic piston is more accurate and
consistent than the weight drop procedure (Marmarou’s impact acceleration model) or the
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FPI model, a must for a study that requires using many animals to replicate the same
brain injury model (Gennarelli, 1994).
Both primary and secondary injury processes occur in TBI. The primary injury
process involves the mechanical aspects of TBI that occur at the time of injury resulting
in massive initial cell death. Secretion of pro-inflammatory cytokines are involved in the
development of cerebral edema and secondary neuronal loss following TBI (Chen, Hung,
Chen et al., 2007). Cytokines are proteins used in cellular communication that are
secreted by microglial cells, astrocytes, and leukocytes. Pro-inflammatory cytokines
would be released following a brain injury and are involved in the increase in CNS injury
(Wayne, 2007). The primary injury process initiates the neurological and biochemical
changes of the secondary injury process (Heath & Vink, 1999). The secondary injury
process includes free radical production, edema formation, and altered activity of Nmethyl-D-aspartate (NMDA) receptors (Heath & Vink, 1999). In addition, a process of
gliosis occurs in which astrocytes accumulate in damaged areas of the central nervous
system (Pekny & Nilsson, 2005).
One proposed pharmacological intervention for a TBI is fluoxetine, a selective
serotonin reuptake inhibitor (SSRI) typically prescribed for depression. Following TBI,
depression is one of the most common symptoms (Rosenthal, Christense, & Ross, 1998),
with manifestations of depression including fatigue, frustration, and poor concentration
(Kreutzer, Seel, & Gourley, 2001). Loubinoux and colleagues have raised the possibility
that serotonin agonists such as fluoxetine may enhance reorganization of motor output
(Loubinoux, Pariente, Boulanour, et al., 2002). The areas of the brain where the
neurotransmitter serotonin is located include the caudal raphe nucleus in the medulla near
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the midline with projections to the cerebellum and spinal cord, as well as the rostral raphe
nuclei in the pons that supplies the forebrain, the limbic-striatal system, hippocampus and
cerebellum, and the prefrontal cortex (Kandel, 1991). In TBI, there is a shearing or
tearing of the axons from the lower brainstem during acceleration/deceleration injuries,
which typically includes the pons and medulla (Van Reekum et al., 2000). Past research
has suggested that serotonin may enhance the production of new neurons by the
activation of serotonin receptors in the brain (Breuzn & Daszuta, 1999). This seems to be
of particular significance in patients with acquired brain injury because the damaged
neurons are theoretically capable of regenerating new tissue in the hippocampus (Gould,
1999). Tsuiki and colleagues (1995) found deficiencies of serotonergic metabolites in the
cerebral spinal fluid of patients with TBI, suggesting that an increase of serotonin in the
brain and cerebral spinal fluid may be beneficial to the clinical outcome of the patients.
SSRIs seem to be successful in reducing and alleviating depression, depression-related
symptoms, and cognitive impairments significantly more than would be accounted for by
natural recovery alone (Perino, Rago, Cicolini, et al., 2001). SSRIs have also been shown
to be successful in treating other symptoms, such as emotional incontinence or
pathological crying following brain injuries (Sloan, Brown, & Pentland, 1992; Seliger,
Hornstein, Flax, et al., 1992). Sloan and colleagues demonstrated a positive effect of
fluoxetine in the treatment of emotional incontinence, in which cases showed marked
improvement within one week (Sloan et al., 1992). Fluoxetine is suggested to improve
selected aspects of cognition, independent of its mood-elevating properties (Carboni,
Vighini, Piubelli, et al., 2006).
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Another proposed pharmacological intervention for TBI is lovastatin. Lovastatin
belongs to a class of drugs referred to as statins, potent inhibitors of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase (Endo, 2004). HMG-CoA is a key
enzyme in cholesterol biosynthesis, leading to the prescribing of statins for the reduction
of serum cholesterol levels. Statins have been shown to have neuroprotective effects
against a variety of CNS diseases, independent of their ability to lower cholesterol
(Asahi, Huang, Thomas, et al., 2005). The neuroprotective effects of statins are due to an
upregulation of endothelial NO synthase (eNOS), resulting in decreased contusion
volume and neurological deficits caused by ischemia and TBI (Endres et al., 1998).
There have been studies conducted on the individual pharmacotherapies of
lovastatin (Asahi et al., 2005; Chen et al., 2007) and fluoxetine (Carboni et al., 2006;
Singh et al., 2000) for stroke and brain injury, however there have not been any studies
investigating the combination of these two existing pharmacological interventions in an
attempt to treat an injury from multiple dimensions. For the treatment of soldiers who
may experience a TBI, it is important to utilize a preventative treatment that will
minimize secondary injury processes to the brain in combination with a pharmacological
agent known for neural plasticity to aid in the repair of resulting damage. Previous
research on the use of lovastatin administered prior to TBI showed the development of
neuroprotective properties that decreased contusion volume in lovastatin-treated animals
as compared to controls, as well as decreased cognitive deficits (Chen et al., 2007).
Studies investigating fluoxetine administration after a brain injury have indicated
improved cognitive abilities, including working memory, relative to increased neural
plasticity (Carboni et al., 2006; Singh et al., 2000). By utilizing lovastatin as a
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preventative measure prior to TBI, the goal is to combat cytokine formation and
inflammation through neuroprotection. Post-TBI administration of fluoxetine as a
treatment is intended to increase neural plasticity and decrease neural deficits.
The purpose of this study is to investigate the effectiveness of using a
combination of existing pharmacological therapies to treat the injuries resulting from
TBI. The hypothesis is that pre-injury lovastatin administration combined with postinjury fluoxetine treatment is effective as a means of combining preventative measures
with post-injury treatment for TBI in personnel within a military combat situation due to
the neuroprotective effects of lovastatin and the neural plasticity properties of fluoxetine.
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CHAPTER II
METHODS

2.1 Subjects
Seventy-six male Long-Evans rats 42 to 45 days of age, weighing 150-174 grams
were purchased from Harlan (Indianapolis) and housed at Louis Stokes Veterans Affairs
Animal Resource Facilities (ARF). Rats were weighed and handled for 10 minutes for 5
consecutive days one day after shipment. All animals had access to food and water ad
libitum. Animals were randomly assigned to one of ten groups: Sham Only (n=8), Sham
Vehicle (n=8), Sham Fluoxetine (n=8), Sham Lovastatin (n=7), Sham FluoxetineLovastatin Combination (n=7), CCI Only (n=7), CCI Vehicle (n=8), CCI Fluoxetine
(n=7), CCI Lovastatin (n=8), and CCI Fluoxetine-Lovastatin Combination (n=8). A
breakdown of the groups can be seen in Table I. Following CCI, surgery, animals were
weighed and handled for 10 minutes daily for 7 consecutive days.
Table I. Distribution of Animals into Groups
Injury
Treatment
Sham
None
Sham
Vehicle
Sham
Fluoxetine
Sham
Lovastatin
Sham
Fluoxetine-Lovastatin Combination
CCI
None

9

n=
8
8
8
7
7
7

N=

CCI
CCI
CCI
CCI

Vehicle
Fluoxetine
Lovastatin
Fluoxetine-Lovastatin Combination

8
7
8
8

76

Post-injury behavioral testing began on day 7 following injury (77-80 days of age) and
continued until day 23 (100-103 days of age). On day 28 post-injury (approximately
105-108 days of age), animals were perfused and brains were extracted for later
histological and immunohistochemical analysis.
2.2 Controlled Cortical Impact (CCI) Surgery
Surgery was performed at 70-73 days of age, with animals in the weight range of
250 to 350 grams. Animals were anesthetized with a mixture of ketamine and xylazine
(75 mg/kg and 5 mg/kg, respectively) delivered intraperitoneally (i.p.). Once surgical
plane was achieved, the incision site was prepared by shaving the animals on the dorsal
side of the head using an electric trimmer followed by betadine scrub using a sterile
cotton pad followed by 70% EtOH on a second sterile cotton pad. The disinfection of the
scalp using betadine and 70% EtOH was alternated a total of three times. Aseptic
procedures were maintained throughout surgery. Rats were placed into the stereotaxic
apparatus (Stoelting, Wood Dale, IL) equipped with a heating pad and the head was held
with ear bars and an incisor bar, in order to maintain the head at a consistent orientation.
Animals were covered in surgical drapes before any surgical procedures were started. A
midline incision was made along the dorsal side of the head to expose the cranium. The
skin covering the scalp was held to the side with hemostats. The surface of the skull was
wiped down using cotton-tipped applicators and sterile saline. Animals received a
5.0mm craniotomy 2.5mm lateral from bregma using a hand held drill (Ram
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Micromotors, East Brunswick, NJ). The craniotomy was performed over the prefrontal
cortex. The controlled cortical impact (CCI) device (myNeuroLab, St. Louis) was
attached to the stereotaxic apparatus. The sterile tip of the CCI device was adjusted to
A/P 3.0mm, D/V -2.2mm, and M/L +/- 2.5mm (Paxinos & Watson, 2007). The tip of the
contusion device compresses the surface of the dura 2.0mm for 2.0 seconds. The impact
velocity of the contusion device was adjusted to 4.0m/second. The area of the contusion
will create an indentation and discoloration in the dura of the medial frontal cortex that
will be evident following removal of the brain via perfusion. Bleeding was controlled
using cotton wipes or surgical gauze. The incision was sutured using stainless steel
wound clips and triple antibiotic ointment (E. Fougera, Melville, NY) was applied to
prevent infection. Sham animals underwent all of the elements of surgical procedure up
to the cortical impact. Animals were transferred to a heated post-surgical cage and
monitored continuously until mobile and monitored daily for two weeks following
surgery. Animals received injections of buprenorphine (0.05 mg/kg) at 12 and 24 hours
post-injury as an analgesic.
Animals were given one week following injury to recover from surgery before
beginning any behavioral testing (Smith et al., 2000). Beginning one day after surgery,
animals were weighed and handled for 10 minutes each.
2.3 Drug Treatment
Lovastatin (Sigma Chemical Co., St. Louis, MO) diluted in sterile saline (0.9%)
was administered at 4 mg/kg/day, i.p., to rodents 63-33 days of age for five days before
injury. This dosage is based on previous literature by Chen and colleagues (2007).
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Fluoxetine (Sigma Chemical Co., St. Louis, MO) diluted in sterile saline (0.9%)
was administered at 10 mg/kg/day, i.p., to rodents 77-80 days of age for one week
following surgery (Windle & Corbett, 2005; Rapp, Baader, Hu, et al., 2004). This dosage
is based on previous literature by Rapp and Colleagues (2004). Fluoxetine administration
at 10 mg/kg/day for 14 consecutive days is considered chronic drug exposure (Rapp et
al., 2004).
2.4 Shaping & Training: Reaching Box Task
A reaching box task was used to test forelimb motor control. All rats were shaped
prior to training for the forelimb reaching task. On the first day of shaping, animals (49
to 52 days of age) were placed in the reaching box (25 x 30 x 35 cm, with a 10 x 4 cm
shelf 2.5 cm from bottom centered over a 1 cm gap for reaching) for 20 minutes along
with their cage mate and quartered yogurt treat rewards (8-in-1 Pet Products, Hauppauge,
NY) were placed on the floor. A diagram of the reaching box is shown in Figure 1.
Figure 1. Diagram of reaching box

Note: Diagram is not drawn to exact scale.
12

Day 2 was the same except that each animal was placed into the box alone. On the third
day, the rewards were placed on the shelf of the box for forelimb reaching. Once animals
had developed a preference for reaching (greater than 70%) with a particular forelimb
and could complete at least 10 reaches in a 10 min span of time, animals began training
(Hsu & Jones, 2006). All animals used in this study developed a preference for one
forelimb over the other.
For training animals were placed individually inside the reaching box and trained
to use the preferred limb exclusively for reaching by presentation of a yogurt treat reward
to the side of the gap opposite to the preferred limb. By utilizing a single forelimb reach
that was used pre-and post-surgery, investigators were looking for small differences in
motor movements. Once the animal had reached a success rate of at least 40% (i.e.
successful retrieval of 4 or more treats from shelf to mouth using the preferred forelimb
over 10 minutes), that day was considered to be the last day of training pre-surgery (Hsu
& Jones, 2006).
Following injury, animals were tested in the reaching box task for assessment of
forelimb dysfunction resulting from TBI. This assessment was done for two days on
days 7 and 21 post-injury (between 77-80 and 98-101 days of age, respectively).
Depending on individual animals, the number of reaches ranged from 0-74 reaches.
2.5 Bilateral Tactile Adhesive Removal Somatosensory (BTARS) Task
At one week post-injury (approximately 79-82 days of age), animals underwent
bilateral tactile adhesive removal testing. Bilaterial tactile adhesive removal
somatosensory (BTARS) test assesses somatosensory dysfunction following injury.
BTARS was performed for a total of 6 days on days 9, 11, 14, 16, 18, and 21 post-injury.
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Each day consisted of two trials, resulting in a total of 12 trials. Stickers (Staples,
Product # 297341) were placed on the top of the animal’s left and right radial forelimb
and the animal was returned to a clear shoebox cage with a top. The animal was timed
using a stopwatch and watched carefully by the investigator. Latency of removal and the
order of removal were recorded. A trial was considered over when the animal removed
both stickers or when two minutes had elapsed. Whether or not the animals were able to
remove the stickers, the stickers were removed from the cage to prevent confusion on the
second trial. There was an intertrial interval of 5 minutes per animal.
2.6 Histology
At 28 days post-injury (approximately 105-108 days of age), animals were
euthanized using a lethal dose of sodium pentobarbitol (75 mg/kg, i.p.) and perfused in
order to obtain the tissue required for later histological analysis (Smith et al., 2000).
Once animals were deeply anesthetized, they were intracardially perfused with 250 ml of
1X phosphate buffered saline (PBS, pH 7.4) followed by 500 ml of paraformaldehyde
solution (PAF, pH 7.4). Tissue was extracted and postfixed in 4% PAF for storage for up
to 6 months. Tissue was then transferred to 30% sucrose at least overnight (or until tissue
sank to the bottom of the container) before being embedded in gelatin. The embedded
tissue was fixed in a solution comprised of 25% glutaraldehyde, 1X phosphate buffer,
and sucrose and rinsed for one hour before sectioning. The tissue was sectioned on a
sliding microtome equipped with a freezing stage. Brains were sectioned coronally at
50µm. Approximately 96 sections from each brain were kept for mounting onto slides
and used for immunohistochemistry and staining.
2.7 Cresyl Violet Staining
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One half of the brain tissue sections were stained with cresyl violet cell body
stain. Digital images were obtained using a digital camera (RT Spot, Sterling Heights,
MI) attached to a light microscope. A total of 3 images from each hemisphere of the
prefrontal cortex contusion area were captured and used to quantify healthy cell numbers.
Images (size: 120,000 µm2) were captured from the center of the injury, 2.5mm from the
midline and 3mm from the dorsal edge of the cortex, as well as 2 images from either side
of the center of the injury. Cells that were round in shape with a dark nucleus contained
inside were counted as healthy cells.
2.8 Immunohistochemistry
The remaining brain tissue sections were labeled with mouse anti-glial fibrillary
acidic protein (GFAP 1:2000, Sigma-Aldrich, Saint Louis, MO) using a free-floating
protocol. The GFAP antibody labels astrocytes and Bergmann glia cells, as well as
gliomas and other glial cell-derived tumors (Hicks, Hewlett, Windle, et al., 2007). Tissue
sections were washed in PBS, then blocked for 1 hour with 5% normal goat serum in
PBS with Triton-X at room temperature. The primary antibody was applied to sections
and allowed to incubate overnight at 4 degrees Celsius. The next day, sections were
washed in PBS at room temperature twice for 10 minutes each. The secondary antibody
(Alexa Fluor 532 goat anti-mouse, 1:2000, Molecular Probes, Eugene, OR) was applied
to sections and incubated for 2 hours at room temperature in the dark. Sections were then
washed in PBS at room temperature, mounted and coverslipped using Vectashield with
Dapi (Vector, Burlingame, CA) for analysis using a fluorescence microscope.
Digital images were obtained using a digital camera (RT Spot, Sterling Heights,
MI) attached to a fluorescent microscope. A total of 3 images from each hemisphere of
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the prefrontal cortex contusion area were captured and used to quantify GFAP-positive
cells. Images (size: 120,000 µm2) were captured from the center of the injury, 2.5mm
from the midline and 3mm from the dorsal edge of the cortex, as well as 2 images from
either side of the center of the injury. GFAP-positive cells fluoresced red under a green
filter.
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CHAPTER III
RESULTS

3.1 Statistical Analysis
Repeated measures analysis of variance (ANOVA) tests and one-way ANOVA
tests were performed using SPSS 15.0 for Windows. For both behavioral tasks, the
between-groups factor was group (Sham Only, Sham Vehicle, Sham Fluoxetine, Sham
Lovastatin, Sham Combination, CCI Only, CCI Vehicle, CCI Fluoxetine, CCI Lovastatin,
and CCI Combination) and the within-groups factor was day of testing. The cresyl violet
and GFAP cell count data were analyzed by taking an average of stained or labeled cells
in sham group brains and comparing them with the average in the CCI group brains
across both hemispheres. A secondary analysis on the cell count data compared sham
group brains to the injured and uninjured hemispheres of the CCI group brains. For all
statistical analysis p<.05 was considered significant for all analyses.
Data were collected from both the reaching box task and the BTARS task. Data
from the reaching box task consisted of the number of successful reaches for each
session. Data collection for the BTARS task consisted of latency of adhesive removal.
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Latency was analyzed using repeated measures ANOVA. The number of reaches from
the reaching box task data was also analyzed using repeated measures ANOVA.
For cell counts, brain tissue was collected from approximately A/P 4.0mm until
A/P 2.0mm (distance anterior from bregma) to collect the area surrounding the injury
site, located at A/P 3.0mm (Paxinos & Watson, 2007). Tissue used for cresyl violet and
GFAP was selected from the center of the injury site. All images were taken from the
prefrontal cortex: two images per hemisphere on either side of the injury site and one
image per hemisphere at the injury site (measured from the intact cortex using a reticle).
3.2 BTARS Data Analysis
Latency to remove the adhesive sticker was analyzed using a repeated measures
ANOVA. The factors included were group (Sham Only, Sham Vehicle, Sham
Fluoxetine, Sham Lovastatin, Sham Combination, CCI Only, CCI Vehicle, CCI
Fluoxetine, CCI Lovastatin and CCI Combination) and day (1-6) as the repeated measure.
Rats became more successful at removing the tactile stimuli on successive trials, as the
main effect of day was statistically significant F(5, 330)=89.213, p<.001. The main effect
of group was also statistically significant F(9, 66)=6.479, p<.001, indicating that group had
an effect on removing the tactile stimuli. There was a significant interaction effect of day
x group F(45, 330)=2.409, p<.001. The pattern of expected outcome did not happen as
hypothesized. The expected outcome for the BTARS behavioral task was to show a
similar pattern of improvement in which sham groups and drug treatment CCI groups
decrease in latency over days. The pattern developed from the data collected can be seen
in Figure 2.
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Figure 2. BTARS Latency Scores by Group

The Sham Only and CCI Only groups followed a similar pattern in terms of
decreasing latency over the first 3 days as can be seen in Figure 2. This suggests that the
two groups that did not receive any injections (i.e., Sham Only and CCI Only) performed
better than the animals that did receive injections regardless of whether the injection was
just saline (vehicle) or a drug treatment. The animals receiving injections took longer to
reach similar levels of latency than those not receiving injections. All means and
standard deviations for the BTARS task are presented in Table II.
Table II. BTARS Means and Standard Deviations
Day 1
Group
Sham Only
CCI Only
Sham Vehicle
CCI Vehicle
Sham
Fluoxetine
CCI
Fluoxetine
Sham
Lovastatin
CCI
Lovastatin
Sham
Combination
CCI
Combination

Day 2

Day 3

Day 4

Day 5

Day 6

Mean
53.82
90.63
113.86
96.75

SD
29.50
26.94
16.25
20.89

Mean
25.56
62.94
109.43
98.13

SD
24.68
31.26
17.15
29.10

Mean
21.13
46.50
83.57
83.94

SD
20.08
31.78
33.23
42.15

Mean
31.94
47.56
82.36
91.25

SD
26.77
33.96
32.59
41.79

Mean
14.00
36.31
69.50
73.31

SD
9.86
25.00
37.64
37.41

Mean
24.00
47.44
74.50
85.19

SD
25.69
39.88
41.37
38.85

106.36

36.10

87.71

33.85

75.14

39.33

67.36

41.51

63.29

39.90

53.43

46.05

116.00

10.58

112.43

16.41

84.07

24.90

62.43

16.25

34.07

11.30

32.36

19.28

120.00

0.00

107.13

23.82

88.19

15.79

70.63

25.50

45.94

16.70

42.31

14.08

112.13

14.60

103.19

20.36

79.19

27.36

61.31

29.48

57.69

28.33

42.50

11.20

119.21

2.08

92.57

21.35

75.43

27.16

55.00

23.18

47.14

14.65

32.64

12.96

117.06

27.23

85.88

28.45

78.63

30.84

55.69

18.52

51.63

17.06

45.19

14.46

Pair-wise comparisons indicated significant group comparisons of Sham Only to
all other groups except CCI Only: Sham Only v. Sham Vehicle, p<.001; Sham Only v.
CCI Vehicle, p<.001; Sham Only v. Sham Fluoxetine, p=.001; Sham Only v. CCI
Fluoxetine, p=.001; Sham Only v. Sham Lovastatin, p<.001; Sham Only v. CCI
Lovastatin, p<.001; Sham Only v. Sham Combination, p=.004; Sham Only v. CCI
Combination, p=.001. Pair-wise comparisons also showed an interaction of CCI Only
with CCI Vehicle as approaching significance at p=.054.
3.3 Reaching Box Data Analysis
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Number of reaches performed was analyzed by repeated measures ANOVA. The
factors included were group (Sham Only, Sham Vehicle, Sham Fluoxetine, Sham
Lovastatin, Sham Combination, CCI Only, CCI Vehicle, CCI Fluoxetine, CCI Lovastatin,
and CCI Combination) and day (Pre-Injury, Post-Injury #1, Post-Injury #2) as the
repeated measure. Rats became more successful at reaching for treats on successive
trials, as the main effect of day was statistically significant F(2, 132)=10.413, p<.001. The
main effect of group was also statistically significant F(9, 66)=2.255, p=.029, indicating
that group had an effect on number of reaches performed. The group x day interaction
was not statistically significant F(18, 132)=0.941, p=.531. The expected pattern would have
been to see the number of reaches increase for each group from Pre-Injury through PostInjury #2, particularly for the drug-treated CCI groups. The unexpected pattern
developed by the reaching box data is shown in Figure 3.
Figure 3. Reaching Box Reaches by Group
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Figure 3 also shows that animals not receiving injections seemed to perform better than
the animals receiving injections on the reaching box task. All means and standard
deviations for the reaching box task are presented in Table III.
Table III. Reaching Box Means and Standard Deviations
Pre-Injury
Post-Injury #1
Post-Injury #2
Group
Mean
SD
Mean
SD
Mean
SD
Sham Only
20.63
17.73
26.00
24.41
33.13 21.67
CCI Only
18.00
18.94
21.63
21.32
23.88 26.90
Sham Vehicle
9.29
5.71
10.71
7.50
11.57
9.96
CCI Vehicle
22.75 21.84 21.63 23.51 22.75 25.55
Sham Fluoxetine
10.57
9.16
13.29
8.14
15.29
8.56
CCI Fluoxetine
11.00
6.90
11.00
3.27
13.71
4.23
Sham Lovastatin
14.13
8.73
16.50
9.70
18.50 11.15
CCI Lovastatin
5.88
4.12
7.25
5.99
7.38
5.81
Sham Combination
5.00
2.08
5.86
2.04
7.71
3.55
CCI Combination
5.38
4.72
8.88
6.22
8.00
5.88

3.4 Cresyl Violet Cell Counts Data Analysis
A one-way ANOVA was calculated on the average number of healthy cells
counted via light microscopy of brain tissue stained with cresyl violet on the sham and
CCI groups. The analysis was statistically significant, F(14, 87) = 68.5, p<.001. All
means and standard deviations for the cresyl violet analysis are presented in Table IV.
Table IV. Cresyl Violet Means and Standard Deviations by Group
Group
Mean
SD
Sham Only
111.00 26.90
Sham Vehicle
124.00 8.96
Sham Fluoxetine
110.00 12.10
Sham Lovastatin
113.00 3.95
Sham Combination
118.00 6.95
CCI Only
74.80
1.66
CCI Vehicle
75.00
4.88
CCI Fluoxetine
58.70
3.01
CCI Lovastatin
66.30
9.23
CCI Combination
61.50
9.73
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The means of each group show there is an overall greater number of healthy cells
in the CCI Only and CCI Vehicle (i.e., non-drug treatment) groups as compared to the
CCI drug treatment groups. A representative example of cresyl violet stained tissue taken
from below the injured area from each group is shown in Figure 4.
Figure 4. Cresyl Violet Microscopy
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J
(A) Sham Only
(B) CCI Only
(C) Sham Vehicle
(D) CCI Vehicle
(E) Sham Fluoxetine
(F) CCI Fluoxetine
(G) Sham Lovastatin
(H) CCI Lovastatin
(I) Sham Fluoxetine-Lovastatin Combination
(J) CCI Fluoxetine-Lovastatin Combination
Bonferoni’s multiple comparisons post-tests were also calculated for the cresyl
violet groups. The post-tests revealed some statistically significant comparisons: Sham
Only vs. all CCI groups were significant at p<.001, Sham Vehicle vs. all CCI groups
were significant at p<.001, Sham Fluoxetine vs. all CCI groups were significant at
p<.001, Sham Lovastatin vs. all CCI groups were significant at p<.001, and Sham
Combination vs. all CCI groups were significant at p<.001.
A second one-way ANOVA was calculated on the average number of healthy
cells counted using light microscopy of brain tissue stained with cresyl violet on the sham
and each hemisphere of the CCI groups. The analysis was statistically significant, F(9,
56) = 34.02, p < .001. All means and standard deviations for the cresyl violet analysis are
presented in Table V.
Table V. Cresyl Violet Means and Standard Deviations by Group and Hemisphere
Group
Mean
SD
Sham Only
111.00
26.09
Sham Vehicle
124.00
8.96
24

Sham Fluoxetine
Sham Lovastatin
Sham Combo
CCI Only Injured
CCI Vehicle Injured
CCI Fluoxetine Injured
CCI Lovastatin Injured
CCI Combo Injured
CCI Only Uninjured
CCI Vehicle Uninjured
CCI Fluoxetine Uninjured
CCI Lovastatin Uninjured
CCI Combination Uninjured

110.00
113.00
118.00
38.71
36.25
38.33
39.76
37.89
114.00
113.80
79.10
92.86
85.17

12.10
3.95
6.95
4.88
5.61
2.83
5.67
2.18
3.09
7.08
5.58
15.69
20.52

The means of the injured and uninjured hemispheres of the CCI groups do not show a
difference among the injured hemispheres of the CCI cell counts. However, the
uninjured hemispheres of the CCI cell counts showed a pattern in which the number of
healthy cells was greater in the non-drug treatment groups as opposed to the drug
treatment groups.
Bonferroni’s multiple comparisons post-tests were also calculated for the cresyl
violet groups. The post-tests revealed some statistically significant comparisons: All
sham groups vs. all CCI Injured hemispheres (p<.001) and all CCI Injured hemispheres
vs. all CCI Uninjured hemispheres (p<.001). All other statistically significant
comparisons are presented in Table VI.
Table VI. Cresyl Violet Additional Significant Bonferroni’s Multiple Comparisons
Bonferroni’s Multiple Comparison Test
Sham Only:
vs. CCI Fluoxetine Uninjured
vs. CCI Combination Uninjured
Sham Vehicle:
vs. CCI Fluoxetine Uninjured
vs. CCI Lovastatin Uninjured
vs. CCI Combination Uninjured
Sham Fluoxetine:

p Value
<.001
<.01
<.001
<.001
<.001
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vs. CCI Fluoxetine Uninjured
vs. CCI Combination Uninjured
Sham Lovastatin:
vs. CCI Fluoxetine Uninjured
vs. CCI Combination Uninjured
Sham Combo:
vs. CCI Fluoxetine Uninjured
vs. CCI Lovastatin Uninjured
vs. CCI Combination Uninjured
CCI Only Uninjured:
vs. CCI Fluoxetine Uninjured
vs. CCI Combination Uninjured
CCI Vehicle Uninjured:
vs. CCI Fluoxetine Uninjured
vs. CCI Combination Uninjured

<.001
<.05
<.001
<.05
<.001
<.05
<.001
<.001
<.01
<.001
<.001

3.5 GFAP Cell Counts Data Analysis
A one-way ANOVA was calculated on the average number of labeled cells
counted via fluorescent microscopy of brain tissue labeled with GFAP on the sham and
CCI groups. The analysis was statistically significant, F(9, 31) = 11.34, p < .001. All
means and standard deviations for the GFAP cell counts are presented in Table VII.
Table VII. GFAP Means and Standard Deviations by Group
Group
Mean
SD
Sham Only
5.56
1.29
Sham Vehicle
3.94
0.20
Sham Fluoxetine
7.46
5.02
Sham Lovastatin
4.34
0.76
Sham Combination
4.27
0.61
CCI Only
11.80
9.11
CCI Vehicle
20.10
6.13
CCI Fluoxetine
14.20
0.833
CCI Lovastatin
12.80
4.68
CCI Combination
16.30
0.72

The means presented for each group show a difference in GFAP-positive cells between
the sham groups and the CCI groups, with the exception of CCI only. A representative
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example of GFAP-positive tissue from the area below the injury area of each group is
shown in Figure 5.
Figure 5. GFAP Microscopy

A

B

C

D

E

F

G

H

27

I
J
(A) Sham Only
(B) CCI Only
(C) Sham Vehicle
(D) CCI Vehicle
(E) Sham Fluoxetine
(F) CCI Fluoxetine
(G) Sham Lovastatin
(H) CCI Lovastatin
(I) Sham Fluoxetine-Lovastatin Combination
(J) CCI Fluoxetine-Lovastatin Combination
Bonferroni’s multiple comparisons post-tests were also calculated for the GFAP
groups. Statistically significant comparisons are presented in Table VIII.
Table VIII. GFAP Significant Bonferroni’s Multiple Comparisons
Bonferroni’s Multiple Comparison Test
p Value
Sham Only:
vs. CCI Vehicle
<.001
vs. CCI Combination
<.01
Sham Vehicle:
vs. CCI Vehicle
<.001
vs. CCI Fluoxetine
<.01
vs. CCI Combination
<.001
Sham Fluoxetine:
vs. CCI Vehicle
<.001
vs. CCI Combination
<.01
Sham Lovastatin:
vs. CCI Vehicle
<.001
vs. CCI Fluoxetine
<.05
vs. CCI Combination
<.01
Sham Combination:
vs. CCI Vehicle
<.001
vs. CCI Fluoxetine
<.01
vs. CCI Lovastatin
<.05
vs. CCI Combination
<.001
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A second one-way ANOVA was calculated on the average number of labeled
cells counted via fluorescent microscopy of brain tissue labeled with GFAP on the sham
and each hemisphere of the CCI groups. The analysis was statistically significant, F(9,
56) = 34.02, p < .001. All means and standard deviations for the GFAP analysis are
presented in Table IX.
Table IX. GFAP Means and Standard Deviations by Group and Hemisphere
Group
Mean
SD
Sham Only
5.56
1.29
Sham Vehicle
3.94
0.20
Sham Fluoxetine
7.56
4.97
Sham Lovastatin
4.34
0.76
Sham Combination
4.27
0.61
CCI Only Injured
20.50
20.04
CCI Vehicle Injured
32.17
7.27
CCI Fluoxetine Injured
24.56
2.03
CCI Lovastatin Injured
10.58
12.13
CCI Combination Injured
22.34
7.67
CCI Only Uninjured
12.84
7.30
CCI Vehicle Uninjured
24.25
11.31
CCI Fluoxetine Uninjured
12.11
2.46
CCI Lovastatin Uninjured
19.67
7.35
CCI Combination Uninjured
15.35
11.01

The analysis from the injured and uninjured hemispheres shows an expected pattern of
GFAP-positive cells in which the injured CCI hemispheres are greater than the uninjured
CCI hemispheres. The exception from this pattern is the lovastatin injured hemisphere
group compared to lovastatin uninjured hemisphere group.
Bonferroni’s multiple comparisons post-tests were also calculated for the GFAP
groups. The post-tests revealed that the following groups were considered statistically
significant: Sham Only vs. CCI Vehicle Injured (p<.001), Sham Vehicle vs. CCI Vehicle
Injured (p<.001), Sham Fluoxetine vs. CCI Vehicle Injured (p<.001), Sham Lovastatin
vs. CCI Vehicle Injured (p<.001), Sham Combination vs. CCI Vehicle Injured (p<.001),
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Sham Combination vs. CCI Fluoxetine Injured (p<.05), Sham Combination vs. CCI
Combination Injured (p<.05), Sham Combination vs. CCI Vehicle Uninjured (p<.05),
CCI Vehicle Injured vs. CCI Lovastatin Injured (p<.05), and CCI Vehicle Injured vs. CCI
Fluoxetine Uninjured (p<.05).
3.6 Further Analyses
Two additional ANOVAs were calculated on the reaching box task using the Preinjury reaching scores to create a baseline. The baseline was created by subtracting the
individual post injury scores (i.e., Post-Injury #1 and Post-Injury #2) from the individual
Pre-injury scores to see the difference in the number of reaches. The differences from the
Post-Injury #1 group were analyzed against injury and treatment. The differences from
the Post-Injury #2 group were also analyzed against injury and treatment. The analyses
did not reveal significant differences.
A correlation was calculated across the post-injury reaching box data, the final
day of the BTARS task data (i.e., Day 6), and the cresyl violet and GFAP cell counts.
The correlation revealed a significant correlation of -.310 between Day 6 of the BTARS
task and healthy cell counts of cresyl violet stained tissue. This relationship was
statistically significant at the .05 level. The negative correlation indicates that as the
latency scores on Day 6 of the BTARS task decreased, the healthy cell counts of cresyl
violet stained tissue increased. No additional significant correlations were observed.
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CHAPTER IV
DISCUSSION
4.1 Current Research
The present study demonstrated that utilizing pre-injury lovastatin, post-injury
fluoxetine, or a combination of both drugs did not improve functional recovery regarding
forelimb motor control. This became evident with the data from the reaching box task.
Most groups saw some improvement in the number of successful reaches from Pre-Injury
through Post-Injury #2, regardless of group (injury and treatment), which may suggest
that an increase in the number of successful reaches could be the result of learning as
opposed to a result of a specific treatment. It is important to note that the number of
successful reaches were higher in groups that did not receive injections as compared to
those that did receive injections. This does not follow the pattern expected by the
investigator. The animals not receiving injections performing better than those that did
receive injections suggests the possibility of a stress effect from receiving injections over
multiple days. When post-injury scores were analyzed using additional ANOVAs
calculated by creating a baseline using the pre-injury scores subtracted from post-injury
scores, no significant differences were revealed.
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The present study also demonstrated that utilizing pre-injury lovastatin and a
combination of lovastatin and fluoxetine did not improve functional recovery regarding
somatosensory dysfunction. This was demonstrated by the data from the BTARS task.
The pairwise comparison of Sham Only v. CCI Fluoxetine revealed significant
differences on Days 1-3, but not on days 4-6. This seems to suggest that Fluoxetine has
some sort of an effect on somatosensory dysfunction in injured animals, although this
effect seems to be limited. It is possible that any positive or therapeutic effect of
Fluoxetine is hidden by the overall variability suggested by the correlation performed
across the behavioral tasks and cell counts data.
Cell counts from the cresyl violet stain suggest that the combination therapy did
not preserve healthy cells counted in the cortex of an injured (CCI) brain as compared to
the number of healthy cells counted in the cortex of an uninjured (sham) brain. Healthy
cells have a tendency to have a round shape with a dark nucleus contained within the cell.
There were significant differences in the number of healthy cells counted between the
sham groups and CCI groups, excluding CCI only. In order to suggest that the
combination therapy of lovastatin and fluoxetine was a viable treatment for traumatic
brain injury, the number of healthy cells counted in the CCI drug treated tissue would
have been expected to be significantly greater than the CCI non-drug treated tissue.
However, the means of each injured group and the group comparisons do not indicate
that the CCI drug treated groups had a significantly greater number of healthy cells in the
stained tissue as compared to the CCI non-drug treated groups.
The second analysis took a look at cell counts from the cresyl violet stain that
looked at differences between the CCI injured and uninjured hemispheres. The analysis
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of the sham brains versus the injured and uninjured hemispheres showed the greatest
number of healthy cells in the sham brains, fewer healthy cells in the CCI uninjured
hemispheres and the fewest healthy cells in the CCI injured hemispheres. Cell counts
from the GFAP labeled tissue suggest that the drug therapy did not significantly decrease
the number of labeled cells counted in the cortex of a CCI brain as compared to the
number of labeled cells in the cortex of a sham brain.
There were significant differences in the number of labeled cells counted between
the sham groups and CCI groups, with the exception of the CCI Only group. In order to
suggest that the drug therapy of lovastatin and fluoxetine was a viable treatment for
traumatic brain injury, the number of labeled cells counted in the CCI drug treated tissue
would have been expected to be significantly less than the CCI non-drug treated tissue.
However, the means of each injured group and the group comparisons do not indicate
that the drug treated CCI groups had a significantly lesser number of labeled cells as
compared to the non-drug treated CCI groups.
In the second analysis, it was revealed that the number of GFAP-positive cells
counted in sham groups were fewer than those in the CCI groups. It was also shown that
GFAP-positive cells were fewer in the CCI uninjured hemispheres as compared to the
CCI injured hemispheres, with the exception of the CCI Lovastatin group in both
hemispheres.
The cell counts data from both the cresyl violet and GFAP procedures both
suggest that a drug therapy utilizing lovastatin and fluoxetine is not an effective treatment
for TBI.

33

Previous research has indicated that both Lovastatin (Asahi et al., 2005; Chen et
al., 2007) and Fluoxetine (Carboni et al., 2006; Singh et al., 2000) were effective as
separate treatments for brain injuries. However, the data presented in the current study
do not follow the data results of previous studies. Referring back to the correlation
performed as an additional analysis, a negative correlation was seen between the final day
of BTARS task testing and the cresyl violet healthy cell counts. As latency decreased on
the final day of the BTARS task, the number of healthy cells counted in the cresyl violet
stained tissue increased. There was no relationship demonstrated between the reaching
box task and the cell counts to one another. The lack of correlation amongst the
remaining items suggests that there is such a high degree of variability that any effect that
does exist could be hidden by the variability itself.
4.2 Limitations
The BTARS latency data revealed that animals that did not receive injections
performed the task better than the animals that did receive injections regardless of
whether the injection was just saline (vehicle) or a drug treatment. This could suggest a
negative impact of stress related to receiving injections on multiple days. One way to
measure stress in individual animals would be to collect blood samples before surgery,
after surgery, and before perfusion to measure levels of the hormone cortisol by means of
immunoassay (Bardi, Bode, Ramirez & Brent, 2005). Another method of measuring
cortisol levels would be to analyze urine from individual animals (van der Hart, de
Biurrun, Czeh, et al., 2005). By analyzing cortisol levels in either blood or urine, a
baseline could be created from sham and CCI animals not receiving injections and
deviations from that baseline could indicate increased stress from receiving injections.
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Of course, the process of measuring cortisol could also lead to unintentional stress in
study animals. In order to avoid additional stress, the drugs could be administered in
either food or water. The animals are still receiving the drug, but the difference is in the
route of administration, completely avoiding the administration of injections altogether.
One limitation to the current study was that the entire study was conducted over
several months, running 3 to 12 animals per group and oftentimes overlapping another
group by about a week. This could have had an impact on later behavioral data due to
investigator learning (i.e., over time being able to run the behavioral tasks more
efficiently).
One possible explanation for the unexpected results of the cell count data could be
in the mechanics of the injury. The CCI contusion device is equipped with autoclavable
metal tips that cause the tissue deformation at the point of contact. The tip size used to
create the CCI injury for this project was 5mm. It is possible that the tip or the velocity
causes an injury that is too large, causing it to mask other processes that have occurred in
the injured cortex. To test this possibility, it would be necessary to perform several
surgeries by utilizing smaller tips and lower the velocity in different animals. When the
behavioral aspects are complete, taking a look at the resulting histology would reveal
whether differences exist from using smaller tips or lowering the velocity.
An acknowledged limitation to the current study is due to the nature of lovastatin
as a drug. Because lovastatin was meant to be used as a preventative measure, the effects
of using lovastatin prior to injury would not be applicable to an everyday situation. Any
observed effects of lovastatin would most likely only apply to soldiers in a military
combat situation where risk of a TBI is greater or in those already prescribed lovastatin
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for cholesterol-lowering reasons who may succumb to a TBI at some point in their life
while still taking the prescription. Because the side effects of lovastatin are considered
mild and short-lived, prescribing the medication as a pre-injury preventative drug could
be considered relatively safe for most soldiers.
4.3 Future Research
Although the combination of lovastatin and fluoxetine was not as hoped for the
treatment of TBI, combined pharmacotherapies should still be explored. Creating the
right combination of existing drugs, drugs currently being developed, or drugs that have
yet to be developed could be the key to treating individuals who have experienced a TBI.
Because TBI is known to have multiple mechanistic processes, it is important to target
the initial massive cell death that begins the injury and to intervene before the secondary
cascade leads to further and more extensive cellular damage. A combined
pharmacotherapy could still be the solution to treating TBI, especially in a military
combat situation.
Future research should also focus on the diagnostic procedures for TBI. A recent
study by Hajszan and Colleagues (2009) illustrated that synapses in the hippocampus are
able to remodel themselves during depression. Because depression is common in TBI
and Post-Traumatic Stress Disorder (PTSD), there is some recognition of the possibility
of comorbid characteristics of PTSD with underlying mild TBI. It is estimated that as
many as 30% of soldiers returning from Operations Iraqi Freedom and Enduring Freedom
suffer from PTSD. Some of the symptoms of PTSD are very similar to symptoms of
TBI, including depression, memory loss, and sudden anger. In fact, a soldier with mild
TBI coupled with PTSD is likely to have greater difficulties adjusting because PTSD is
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exacerbating some elements of the TBI (Elsevier, 2009). By employing more accurate
procedures for TBI and PTSD, nurses and physicians may have more success treating a
multi-faceted injury when there are diagnostic procedures which can pinpoint both the
primary and secondary elements of what a patient is suffering from.
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